HLS Therapeutics Inc. EBITDA for the year ending December 31, 2024: USD 17.22 M

HLS Therapeutics Inc. EBITDA is USD 17.22 M for the year ending December 31, 2024, a 33.64% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • HLS Therapeutics Inc. EBITDA for the year ending December 31, 2023 was USD 12.88 M, a -28.41% change year over year.
  • HLS Therapeutics Inc. EBITDA for the year ending December 31, 2022 was USD 18.00 M, a -29.18% change year over year.
  • HLS Therapeutics Inc. EBITDA for the year ending December 31, 2021 was USD 25.41 M, a 9.56% change year over year.
  • HLS Therapeutics Inc. EBITDA for the year ending December 31, 2020 was USD 23.19 M, a 17.46% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)